9 completed, 2 unknown, 1 active not recruiting, 1 not yet recruiting. 14 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 14 | Completed 9, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
Follow Bone Loss: new trials by email Literature Review of Bone Loss trials Research Report on Bone Loss
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Osteogenic Action of a Medical Device Based on Beta-tricalcium Phosphate (BTCP) Medical device: beta-tricalcium phosphate, Bovine Hydroxyapatite - Bone Loss, Regenerative Inflammation | Phase 4 | Not yet recruiting | Mario Pérez Sayáns | 30 | 2025-07-01 | 2025-04-24 |
| Osteogenic Action of a Biphasic Bioceramic With Statin in a Third Molar Extraction Model Biphasic bioceramic of tricalcium phosphate and hydroxyapatite with simvastatin, Bovine Hydroxyapatite - Bone Loss, Regenerative Inflammation | Phase 4 | Unknown | Mario Pérez Sayáns | 30 | 2024-03-02 | 2024-04-03 |
| Bone, Exercise, Alendronate, and Caloric Restriction Bisphosphonate, Resistance Training/Bone-Loading Exercise, Placebo - Bone Loss | Phase 4 | Recruiting | Wake Forest University Health Sciences | 900 | 2023-06-08 | 2026-06-09 |
| LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet - Change in Bone Mineral Density, Bone Loss | Phase 4 | Active not recruiting | Insud Pharma | 1536 | 2022-03-28 | 2026-04-09 |
| Regenerative Potential of Advanced Platelet Rich Fibrin and Bioactive Glass (Perioglas®). open flap debridement and filled with A-PRF ( Advanced platelet rich fibrin), open flap debridement and filled with Bioactive glass (Perioglas®), open flap debridement and filled Bioactive glass (Perioglas®) and A-PRF - Chronic Periodontitis, Bone Loss | Phase 4 | Completed | Maharishi Markendeswar University (Deemed to be University) | 48 | 2020-12-01 | 2022-11-08 |
| Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery Denosumab, Placebo, Zoledronic Acid - Bariatric Surgery Candidate, Bone Loss | Phase 4 | Completed | Massachusetts General Hospital | 36 | 2020-08-24 | 2025-10-29 |
| BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study B/F/TAF, TDF/3TC/EFV or DTG or NVP, DMPA - Bone Loss | Phase 4 | Unknown | MU-JHU CARE | 330 | 2019-12-03 | 2023-04-07 |
| Influence of the Implant Connection on Facial Tissues Maturation implantology - Bone Loss, Periodontal Bone Loss | Phase 4 | Completed | University of Milan | 104 | 2018-11-01 | 2019-11-14 |
| Weight Loss With Risedronate for Bone Health Risedronate Sodium 150 MG, Placebo - Bariatric Surgery Candidate, Bone Loss | Phase 4 | Completed | Wake Forest University Health Sciences | 24 | 2018-06-15 | 2021-02-09 |
| Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI) teriparatide, weight-bearing - Osteoporosis, Bone Loss | Phase 4 | Completed | Thomas J. Schnitzer | 12 | 2009-06-01 | 2013-07-11 |
| Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy risedronate - Bone Loss, Osteoporosis | Phase 4 | Completed | Susan L. Greenspan | 109 | 2007-09-01 | 2017-10-13 |
| Antiepileptic Drugs and Osteoporotic Prevention Trial Risedronate, Placebo + Calcium and Vitamin D - Epilepsy, Bone Loss | Phase 4 | Completed | Boston VA Research Institute, Inc. | 80 | 2006-06-01 | 2015-07-24 |
| Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty Risedronate, Placebo - Bone Loss | Phase 4 | Completed | Danderyd Hospital | 78 | 2006-04-01 | 2014-09-19 |
| A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients. Pamidronate - Bone Loss | Phase 4 | Completed | Novartis Pharmaceuticals | 126 | 2000-06-01 | 2010-05-17 |
Bone Diseases, Metabolic (14) · Osteoporosis (5) · Weight Loss (2) · Alveolar Bone Loss (1) · Breast Neoplasms (1) · Chronic Periodontitis (1) · Epilepsy (1) · Fractures, Bone (1) · Seizures (1) · Spinal Cord Injuries (1)
Bone Diseases (14) · Metabolic Diseases (14) · Musculoskeletal Diseases (14) · Nutritional and Metabolic Diseases (14) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (3) · Body Weight (2) · Body Weight Changes (2) · Central Nervous System Diseases (2) · Mouth Diseases (2) · Nervous System Diseases (2) · Periodontal Diseases (2) · Stomatognathic Diseases (2) · Wounds and Injuries (2) · Bone Resorption (1)
Risedronic Acid (4) · Bio-Oss (1) · Bioglass (1) · Calcium (1) · Denosumab (1) · Diphosphonates (1) · Durapatite (1) · Exercise (1) · Medroxyprogesterone Acetate (1) · N,N-dimethyl-4-anisidine (1) · Nevirapine (1) · Pamidronate (1) · Simvastatin (1) · Tablets (1) · Teriparatide (1)
Mario Pérez Sayáns (2) · Wake Forest University Health Sciences (2) · Boston VA Research Institute, Inc. (1) · Danderyd Hospital (1) · Insud Pharma (1) · MU-JHU CARE (1) · Maharishi Markendeswar University (Deemed to be University) (1) · Massachusetts General Hospital (1) · Novartis Pharmaceuticals (1) · Susan L. Greenspan (1) · Thomas J. Schnitzer (1) · University of Milan (1)
United States (7) · Spain (2) · Czechia (1) · India (1) · Italy (1) · Poland (1) · Sweden (1) · Uganda (1) · United Kingdom (1)
Antonio A Lazzari, MD (1) · Enrico Colli, MD (1) · Fabio Camacho Alonso, phD (1) · Flavia Kiweewa Matovu, MBChB, MSc (1) · John Cunningham, MD (1) · Kristen Beavers, PhD (1) · Kristen M Beavers, PhD (1) · Manisha Thakore, MD (1) · Phillip Dussault, Pharm D (1) · Susan L. Greenspan, MD (1) · Thomas J Schnitzer, MD, PhD (1)
PMID 19393473, PMID 32066431, PMID 33103032, PMID 38979716
R01AG074979 (1)